Disease Landscape and Forecast Insights

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s semaglutide SC (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have gained popularity in…

Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…

The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics and targeted oral therapies. The well-established TNF-α…

COPD is a progressive respiratory condition that primarily affects adults, particularly smokers and individuals exposed to environmental pollutants. The COPD therapeutics market in China includes a…

Clarivate Epidemiology’s coverage of malignant pleural mesothelioma (MPM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of mesothelioma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

In the dynamic Parkinson’s disease (PD) market, recent advancements have been matched by notable challenges. Although the introduction of new brands, including Acorda’s Inbrija and AbbVie’s…

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

TNF-alpha inhibitors (e.g., Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira) are entrenched in the U.S. ulcerative colitis (UC) therapy market. Alternative treatment options…